180 Life Sciences(ATNF.US)

Company Encyclopedia
View More
name
180 Life Sciences
ATNF.US
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
1.896 T
ATNF.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    180 Life Sciences Corp. Completes Share Transactions: 1,658 Common Shares Issued at $2.65/Share; 1,940,112 Shares in Process from Pre-Funded Warrants at $0.0001/Share

    180 Life Sciences Corp. has completed share transactions involving ETHZilla Corporation. On August 14, 2025, 1,658 common shares were issued at $2.65 each, and on August 19, 2025, 1,940,112 shares were purchased from pre-funded warrants at $0.0001 each. Both transactions were exempt from registration under the Securities Act of 1933, involving accredited investors only.

    Reuters·
    US
    ATNF
    0.00%
    Reuters·
    US
    ATNF
    0.00%

    U.S. stock market update: 180 Life Sciences down 11.50%

    180 Life Sciences fell 11.50%; AbbVie rose 0.38%, with a transaction volume of USD 176 million; Soleno Therapeutics fell 11.96%, with a transaction volume of USD 169 million; Precigen rose 50.00%, with a transaction volume of USD 152 million; Amgen rose 1.13%, with a market value of USD 158 billion

    Tracking Unusual Activity·
    US
    ATNF
    0.00%
    US
    ETHZ
    -1.80%
    Tracking Unusual Activity·
    US
    ATNF
    0.00%
    US
    ETHZ
    -1.80%

    Pre-market hot trades in US stocks: 180 Life Sciences pre-market down 8.54%

    180 Life Sciences pre-market down 8.54%; Perfect Moment pre-market up 102.48%; Dragonfly Energy pre-market up 75.71%; Oriental Rise pre-market up 49.62%

    Tracking Unusual Activity·
    US
    ATNF
    0.00%
    US
    ETHZ
    -1.80%
    Tracking Unusual Activity·
    US
    ATNF
    0.00%
    US
    ETHZ
    -1.80%

    180 Life Sciences Stock Slides After-Hours As Ethereum's Decline Triggers Massive Sell-Off

    180 Life Sciences Corp. (ATNF) shares fell 1.45% in after-hours trading, following a significant decline in Ethereum (ETH), which dropped below $4,500. This decline led to a 28% decrease in ATNF's stock during regular trading. The company holds 82,186 ETH, valued at over $381 million, and plans to rebrand as ETHZilla Corporation. Despite recent surges, the stock has seen a 271% increase over the past month. Billionaire Peter Thiel holds a 7.5% stake in the firm. As of now, ETH is trading at $4,638.80, down 3% in the last 24 hours.

    Benzinga·
    US
    ATNF
    0.00%
    US
    ETHZ
    -1.80%
    Benzinga·
    US
    ATNF
    0.00%
    US
    ETHZ
    -1.80%

    U.S. Stock Market Midday Update: 180 Life Sciences down 30.16%

    180 Life Sciences fell 30.16%; CRISPR therapy rose 1.26%, with a transaction volume of USD 500.7 million; Fortress Biotech fell 1.63%, with a transaction volume of USD 360.9 million; Gilead Sciences fell 0.87%, with a transaction volume of USD 341.6 million; AbbVie rose 0.15%, with a market capitalization of USD 356.4 billion

    Tracking Unusual Activity·
    US
    ATNF
    0.00%
    US
    ETHZ
    -1.80%
    Tracking Unusual Activity·
    US
    ATNF
    0.00%
    US
    ETHZ
    -1.80%
    © 2026 Longbridge｜Disclaimer